Medical diseases, conditions and technologies

  • Patients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents
  • January 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer
  • WHA70: Statement of India (SEARO) on cancer prevention and control in the context of an integrated approach
  • KEI Statements on World Health Assembly Committee Passage of Cancer Resolution | May 30, 2017
  • Press Release: Coalition for Affordable T-DM1 Asks UK Government to grant compulsory licenses on Roche breast cancer drug
  • Video: Coalition for Affordable T-DM1 Crown Use Request (in UK, for patents on cancer drug Kadcyla)
  • India Intellectual Property Appeals Board (IPAB) upholds compulsory license on cancer drug in Bayer v Natco
  • 4 March 2013: KEI statement on IPAB order (Natco versus Bayer) on cancer drug sorafenib tosylate
  • Proposal for the inclusion of trastuzumab on the WHO EML for the treatment of HER2-Positive Breast Cancer
  • India Patent Office denies patent for prostate cancer drug sold under brand name Xtandi, generic name enzalutamide
  • Abbvie seeks EU monopoly of combinations of Hepatitis C drugs
  • Cancer: Annual deaths compared to new cases in 2004, for 16 types of cancer and 4 World Bank income groups
  • US Congressional efforts to control the cost of DoD funded drugs
  • Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.
  • FOIA document: In 2007, US Ambassador Ralph Boyce was pleased that Abbott withdrew life saving drugs from market in Thailand
  • KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)
  • Cancer
  • The Bayer compulsory license case involving patents for the cancer drug sorafenib
  • 2017: Salubris Biotherapuetics: Bispecific, Biparatopic Antibody-Drug Conjugate for Human Liver Cancers
  • On World Cancer Day, do we celebrate the approval of Pfizer’s $118,200 drug Ibrance?
  • Front page New York Times story explores Kite Pharma’s profitable relationship with NIH regarding expensive cancer drug
  • Disparities in Asthma Outcomes in 2004
  • Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?
  • Incentives for R&D on new uses of existing drugs
  • Drugs
  • Survey: 7 out of 8 persons say US residents should not pay more than other high income countries for NIH funded drugs
  • The production of generic drugs in India: A new trade agreement with the EU would hinder access to drugs in developing countries
  • NIH support for research on selected drugs
  • WHA70 – Side Event on Addressing Access Barriers and Affordability Challenges for Cancer Drugs – 24 May 2017
  • Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs
  • IMS Health May 2015 comments on patient access to oncology drugs
  • drugsalesdata
  • Data on Selected Cancer Drugs
  • John Edwards calls for prizes to replace monopolies as innovation incentive for new drugs
  • What’s a counterfeit? And how many counterfeit drugs are there?
  • Recent ICE Press regarding counterfeit of pharmaceutical drugs
  • Man gets three years probation, no jail time, for importing counterfeit drugs into USA
  • Commentary on Hillary Clinton’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs
  • Research note on oncology drugs, including trial size and orphan drug status
  • KEI asks FTC to Investigate Gilead Effort To Control Market For AIDS Drugs Ingredients
  • In the first 7 months of 2011, the FDA has approved 18 new molecular entity pharmaceutical drugs (and no biologic NMEs)
  • Congressional Hearings in 110th U.S. Congress, on pharmaceutical drugs (including trade issues)
  • TPP on registration of drugs, bans requirements to disclose or consider certain financial or pricing data.
  • Relative prices of brand and generic drugs
  • John Edwards calls for prizes to replace monopolies as innovation incentive for new drugs
  • U.S. DoS Cable: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS
  • KEI’s supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs
  • Dept of State cables on Brazil negotiations on prices and patents for AIDS drugs
  • Cancer morality, compared to spending on drugs, in EU
  • 32 Members of US House of Representatives ask USTR to sanction Canada for not granting patents on drugs
  • DG-Enterprise – data exclusivity prevents access to life saving drugs (in the EU), even in an emergency situation
  • FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
  • Roche Revenues for HER2+ Oncology Drugs since FDA Approval
  • Call for Action on Cancer Drugs by YP-CDN, KEI, and UAEM at 67th World Health Assembly
  • Members of Congress and Governors backing PhRMA/BIO, calling for 12 years data protection for biologic drugs in TPP
  • For expensive cancer drugs, rationing of access is not the only solution
  • May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic tests
  • Tuberculosis outcomes by WHO region and income in 2004
  • Cancer Moonshot Blue Ribbon Panel Does Not Address Pricing, Alternative Funding Models
  • Fred Hutchinson Cancer Center often fails to disclose federal funding of inventions on initial patent
  • Some recent cancer drug prices
  • Recent cancer drug prices
  • Printer-friendly version Send by email Send by email